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Abstract
Purpose Isocitrate dehydrogenase 1 (IDH1) mutations are associated with improved survival in gliomas. Depending on 
the IDH1 status, TERT promoter mutations affect prognosis. IDH1 mutations are associated with alpha-thalassemia/mental 
retardation syndrome X-linked (ATRX) mutations and alternative lengthening of telomeres (ALT), suggesting an interaction 
between IDH1 and telomeres. However, little is known how IDH1 mutations affect telomere maintenance.
Methods We analyzed cell-specific telomere length (CS-TL) on a single cell level in 46 astrocytoma samples (WHO II-IV) 
by modified immune-quantitative fluorescence in situ hybridization, using endothelial cells as internal reference. In the same 
samples, we determined IDH1/TERT promoter mutation status and ATRX expression. The interaction of  IDH1R132H mutation 
and CS-TL was studied in vitro using an  IDH1R132H doxycycline-inducible glioma cell line system.
Results Virtually all  ALTpositive astrocytomas had normal TERT promoter and lacked ATRX expression. Further, all 
 ALTpositive samples had  IDH1R132H mutations, resulting in a significantly longer CS-TL of  IDH1R132H gliomas, when compared 
to their wildtype counterparts. Conversely, TERT promotor mutations were associated with  IDHwildtype, ATRX expression, 
lack of ALT and short CS-TL. ALT, TERT promoter mutations, and CS-TL remained without prognostic significance, when 
correcting for IDH1 status. In vitro, overexpression of  IDHR132H in the glioma cell line LN319 resulted in downregulation 
of ATRX and rapid TERT-independent telomere lengthening consistent with ALT.
Conclusion ALT is the major telomere maintenance mechanism in  IDHR132H mutated astrocytomas, while TERT promoter 
mutations were associated with  IDHwildtype glioma.  IDH1R132H downregulates ATRX expression in vitro resulting in ALT, 
which may contribute to the strong association of  IDH1R132H mutations, ATRX loss, and ALT.
Keywords Isocitrate dehydrogenase · D2HG · Telomerase · Telomere length · Q-FISH · TERT promoter · ALT · ATRX
Introduction
Gliomas are the most common primary brain tumors in adults 
and represent a histologically defined entity with a high 
molecular heterogeneity determining prognosis and response 
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to therapy [1, 2]. Along this line, determination of isocitrate 
dehydrogenase (IDH) 1 mutation status became mandatory in 
the updated 2016 WHO classification [3]. IDH1 mutations are 
driver mutations of low-grade gliomas and found in 80% [4] 
but are not detectable in primary glioblastoma (GBM) [2, 5]. 
The most common IDH1 mutations in glioma (> 95%) result 
in an amino acid substitution at arginine 132 (R132), which 
resides in the enzyme’s active site [4]. Despite the abundance 
of evidence in support of a major pathophysiological and prog-
nostic role of IDH1 mutations [6–8], the precise mechanism 
of how IDH1 mutations modulate malignancy is still not com-
pletely understood. While IDH1 has a major role in the citric 
acid cycle, R132H mutation  (IDHR132H) results in a gain of 
function;  IDH1R132H catalyzes conversion of alpha-ketoglutar-
ate into the oncometabolite D-2-hydroxyglutarate (D2HG) [9]. 
D2HG inhibits dioxygenases that depend on alpha-ketoglutar-
ate, like Ten-eleven translocation methylcytosine dioxygenase 
1 (TET1) and histone-lysine demethylases [10]; this results in 
increased CpG island methylation [11] and a stable reshaping 
of the epigenome (CpG island methylation phenotype, CIMP) 
changing transcriptional programs and altering the differentia-
tion state [12].
Telomeres determine the proliferative capacity of mam-
malian cells. Telomere length (TL) shortens with each cell 
division until cell proliferation is arrested once the maximal 
number of cell divisions is reached (“Hayflick limit”). In case 
of further replication, cells undergo chromosomal instability 
and induction of apoptosis. Expression of human telomerase 
reverse transcriptase (TERT) allows for the stabilization and 
elongation of telomeres. Telomere maintenance mechanisms 
(TMM) are necessary for immortality of cancer cells by over-
coming genetic instability associated with critical telomere 
shortening [13].
TERT promoter mutations  (TERTpmut) are common in 
glioma and found in 80% of all primary GBM [14–16], repre-
senting one possible TMM.  TERTpmut disrupt the tight tran-
scriptional suppression of TERT in somatic cells resulting in 
increased TERT expression and telomerase activity in vitro 
in glioma [17].
A mechanism of homologous recombination [18] to main-
tain TL, known as “alternative lengthening of telomeres” 
(ALT), was also identified in gliomas. About 20–63% of 
adult low-grade glioma and 11% of adult GBM use ALT as 
an additional mechanism for telomere maintenance [19, 20]. 
Dysfunction of the α-thalassemia/mental retardation syndrome 
X-linked (ATRX)/death-associated protein 6 (DAXX) com-
plex is known to result in ALT along with more widespread 
genomic destabilization [21–23]. ATRX and DAXX are cen-
tral components of a chromatin-remodeling complex required 
for the incorporation of H3.3 histone proteins into the telo-
meric regions of chromosomes [24, 25]. 75% of grade II–III 
astrocytomas and secondary GBM harbor ATRX abberations 
[26–28] linking IDH1 mutations with ATRX and ALT.
Despite the strong associations observed, few data is 
available how the different pathways interact on telomere 
maintenance. The aim of this study was to investigate the 
interplay among IDH1, TL, ATRX and TERT/ALT using a 
newly developed distinctive methodology that allowed deter-
mination of glioma cell-specific telomere length (CS-TL) on 
a single cell level.
Materials and methods
Patients
Tissue samples from 46 astrocytoma patients were 
included for the study. The Regional Committee on Health 
Research Ethics approved the study for Southern Denmark 
(S2DO90080) and Danish Data Protection Agency (file 
number: 2009-41-3070) and all patients provide informed 
consent. The use of tissue was not prohibited by any patient 
according to the Danish Tissue Application Register. All 
methods were performed in accordance with the relevant 
guidelines and regulations. All patients underwent pri-
mary surgery between 1991 and 2005 at the Department 
of Neurosurgery, Odense University Hospital, Denmark. 
All cases were independently reviewed and reclassified by 
M.D.S and B.W.K. (senior neuropathologist) according to 
the 2016 WHO guidelines [2] as described in [29]. Clinical 
data were extracted from the respective electronic patient 
journal. Clinical and neuropathological characteristics of the 
astrocytoma patients are shown in Table 1.
Immunohistochemistry
Formaldehyde-fixed paraffin embedded (FFPE) sections of 
three µm from pre-surgery tissue biopsies were used for this 
study. FFPE sections were stained as described previously 
using primary antibodies against  IDH1R132H (H09, 1:100, 
Dianova, Germany) [30] and ATRX [29] (HPA001906, 
1:100, Atlas Antibodies, Sweden) epitopes.
DNA extraction, polymerase chain reaction 
and mutational analysis by sequencing
Mutations in the TERT promoter region were identified by 
PCR and Sanger sequencing as described previously [31]. 
The detailed protocol can be found in the Supplementary 
Materials and methods.
Cell culture, proliferation and clonogenicity
For the cell culture experiments the doxycycline-inducible 
GBM cell line LN319 expressing IDH1 wildtype  (IDH1WT) 
and  IDH1R132H was used. Cells were cultured in Dulbecco’s 
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Modified Eagle Medium (DMEM) (Gibco, Germany) sup-
plemented with 10% tetracycline-free fetal calf serum (FCS) 
(Clontech, USA) and standard antibiotics (Gibco, Germany). 
1 µM doxycycline was used (Sigma Aldrich, Germany) to 
induce expression. Cell proliferation was assessed using the 
CellTiter-Blue Assay (Promega, Germany) as described pre-
viously [32] using the FLUOstarOPTIMA (BMG Labtech, 
Germany) fluorometer.
For colony-forming unit assays, 2500 cells/well were 
seeded in a 6-well format for 10 days before colonies were 
fixed and stained with Cristal Violet (Sigma, Germany). For 
agar assays, 8000 cells/well were seeded in a 6-well format 
and incubated for 3 weeks before cells were stained with 
Cristal Violet. Images were acquired with a Cool Snap™ 
HQ2 digital camera (Photometrics, USA) on an Axiophot 2 
microscope (Carl Zeiss, Germany). Quantification was done 
Table 1  Patient characteristics 
and pathology
Diffuse astrocytoma Anaplastic astrocytoma Glioblastoma All
Patients (n) 24 9 13 46
Age
 Mean 45.2 47.6 65.3 51.4
 Range 2.6–78.5 29.5–71.0 49.4–77.5 2.6–78.5
Sex (n)
 Male 14 (58.3%) 3 (33.3%) 10 (76.9%) 27 (58.7%)
 Female 10 (42.7%) 6 (66.7%) 3 (23.1%) 19 (41.3%)
Status (n)
 Alive 3 (12.5%) 0 (0%) 0 (0%) 3 (6.5%)
 Dead 21 (87.5%) 9 (100%) 13 (100%) 43 (93.5%)
Overall survival (months)
 Median 76.9 24.0 7.5 32.6
 Range 3.4–280.0 4.7–48.8 1.5–34.2 1.5–280.0
IDH1 status (n)
 Mutated 18 (75.0%) 4 (44.4%) 1 (7.7%) 23 (50.0%)
 Wildtype 6 (25.0%) 5 (55.6%) 12 (92.3%) 23 (50.0%)
ATRX status (n)
 Loss 20 (83.3%) 4 (44.4%) 4 (30.8%) 28 (60.9%)
 Retained 4 (16.7%) 5 (55.6%) 9 (69.2%) 18 (39.1)
1P/19Q status (n)
 CO-DEL 0 0 0 0
 1P-DEL 0 1 (11.1%) 1 (7.7%) 2 (4.3%)
 19-DEL 0 0 0 0
 NON-DEL 5 (20.8%) 2 (22.2%) 2 (15.3%) 9 (19.6%)
 Not determined 19 (79.2%) 6 (66.7%) 10 (76.9%) 35 (76.0%)
hTERT promoter mutation
 Mutated 6 (25.0%) 3 (33.3%) 9 (69.2%) 18 (39.1%)
 C228T 5 (83.3%) 2 (66.7%) 8 (88.9%) 15 (83.3%)
 C250T 1 (16.7%) 1 (33.3%) 1 (11.1%) 3 (16.7%)
 None 17 (75.0%) 5 (55.6%) 4 (30.8%) 26 (56.5%)
 Not determined 1 (4.1%) 1 (11.1%) 0 2 (4.3%)
ALT status
 Negative 12 (50%) 5 (55.6%) 12 (92.3%) 29 (63.0%)
 Positive 12 (50%) 4 (44.4%) 1 (7.7%) 17 (37.0%)
KI67 proliferation rate
 Mean (%) 3.3 9.7 10.2 6.7
 Range (%) 0–30 3–20 2–35 0–35
CS-TL
 Median 11.8 13.6 3.5 11.0
 Range − 1.1 to 36.7 − 3.9 to 31.5 − 6.0 to 25.2 − 6.0 to 36.7
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using ImageJ software (open source). Results are means of 
three repeated experiments.
(D)‑2‑hydroxyglutarate (DGH2) assay
The DGH2 assay used was based on an enzymatic assay as 
previously described [9]. The detailed protocol can be found 
in the Supplementary Materials and methods.
RNA extraction, cDNA synthesis and mRNA 
expression
Determination of TERT and ATRX mRNA expression was 
carried out as described presviously[32]. Gene expression 
is expressed in fold change according to the 2−ΔΔct method. 
Additional information can be found in the Supplementary 
Materials and methods.
Quantitative fluorescence in situ hybridization 
(Q‑FISH)
TL analysis was done by a modified protocol of immuno-
quantitative fluorescence in situ hybridization (Q-FISH) as 
previously described [31–35]. FFPE sections of the cohort 
were deparaffinized and rehydrated before antigen retrieval 
in 10 mM citrate buffer (pH 6.0). Slides were permeabilized 
with 0.2% Triton X-100 and blocked for 30 min in serum-
free buffer (Rotiblock 1:10, Roth, Germany). Actin fibers 
were first stained with primary antibody mouse anti-human 
alfa-SMA (1:200, DAKO, Germany) and a goat anti-mouse 
Alexa Fuor 633 (1:100, Thermo Fisher, Germany) as sec-
ondary antibody. Next, cells were post-fixed in formalin for 
30 s and dehydrated with increasing ethanol series before 
telomere staining. For cells in culture, cells were recovered 
from culture, fixed in methanol:acetic acid (3:1), cytospin, 
air dried and dehydrated with ethanol before telomeres 
were stained. Telomere staining consisted in providing a 
hybridization mixture containing the Cy3-(C3TA2) peptide 
nucleic acid (PNA) probe (Panagene, South Korea) to the 
slides for 3 min at 85 °C for DNA denaturation. Slides were 
then hybridized for 2 h at room temperature in a humidified 
chamber. Next, slides were washed with a formamide-based 
buffer, DAPI stained, and mounted with Vectashield antifade 
mounting medium (Vector Labs, USA). Fluorescence was 
acquired with the high-resolution laser-scanning microscope 
LSM710 (Zeiss, Germany). H&E stained sections were ana-
lyzed in parallel for all cases to identify tumor areas. Fluo-
rescent image capture was done with ×63 optical magnifica-
tion and ×1.2 zoom. A multi-tracking mode of 0.5 μm-steps 
was used to acquire images of DAPI, Cy3 and Alexa Fluor 
633 stainings. Maximum projection of five single consecu-
tive steps of 1.2 µm each was done for TL quantification 
using Definiens software (Definiens, Germany). Nuclei and 
telomeres were detected based on the respective DAPI and 
Cy3 intensity. Alfa-SMA was used to identify endothelial 
cells that were used as an internal control to correct for TL 
inter-individual variability [32–38]. A mean number of 150 
tumor cells and 100 endothelial cells were assessed per case. 
To determine the tumor cell-specific telomere length (CS-
TL), the difference (Δ telomere length) between the TL of 
astrocytoma cells and the TL of endothelial cells was calcu-
lated and designated in arbitrary units (a.u.) of fluorescence.
ALT assessment
All astrocytoma cases were assessed for the presence of ALT 
phenotype using telomere Q-FISH staining. ALT positivity 
was identified by large, ultrabright, clumpy, intranuclear foci 
of telomere FISH signals, as previously described [20, 21]. 
A tumor was defined as ALT-positive, when the following 
two criteria were fullfilled: (1) the presence of ultra-bright 
intranuclear foci of telomere FISH signals (ALT-associated 
telomeric foci), with integrated total signal intensities for 
individual foci being > 10-fold the mean signal intensities 
per cell of all telomeric signals from endothelial cells within 
the same case and (2) the number of cells with ALT-associ-
ated telomeric foci being 1% or more of the total number of 
tumor cells assessed per case [20, 21].
ATRX and TERT Immunofluorescence and western 
blotting
Immunofluorescence for ATRX and TERT followed previ-
ously published protocols [32, 35, 37]. Western blot was car-
ried out according to previous published standard protocols. 
The detailed protocol can be found in the Supplementary 
Materials and methods.
Statistical analysis
The data was collected via Microsoft Excel 2007 and ana-
lyzed using Stata version 15 (StataCorp LP, USA) or Graph-
Pad Prism 5.0 (GraphPad Software Inc, USA). ANOVA with 
Bonferroni correction was used for comparison of more than 
two groups. Student’s unpaired t test was used to compare 
differences between two groups. Fisher’s exact test was used 
to analyze categorical data. Overall survival was defined 
from the day of initial surgery until death or date of censor-
ing (July 1st, 2018). Survival data were analysed and we 
using Kaplan–Meier and the multivariate Cox regression 
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Fig. 1  Glioma cell-specific telomere length in  IDH1WT and 
 IDH1R132H glioma. a Overview of biomarkers status in glioma 
patients (n = 46). b Telomere length in glioma vs endothelial cells. c 
Telomere length (in arbitrary units, a.u.) in  IDH1WT and  IDH1R132H 
glioma samples; d Telomere length (in a.u.) in  IDH1WT and 
 IDH1R132H glioma stratified by WHO tumor grade (DA diffuse astro-
cytoma, AA anaplastic astrocytoma, GBM gliobastoma multiform); 
e Kaplan–Meier survival curves (in months) of patients with CS-TL 
below (CS-TLshort) or above median; f Kaplan–Meier survival curves 
(in months) of patients with CS-TL below (CS-TLshort) or above 
median stratified based on IDH1 mutational status
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model to adjust for age, WHO grade, and IDH1 status. Sur-
vival curves were compared using the log-rank test.
Results
Association of  IDH1R132H mutations and telomere 
length
The incidence of  IDH1R132H mutations in our cohort was 
50% (Fig. 1a, Table 1). Single cell-based telomere analysis 
using modified immuno-Q-FISH (Supplementary Figure 
S1A, B) revealed significantly longer TL in astrocytoma as 
compared to endothelial cells (p < 0.0001) and a substan-
tial inter-individual variability (Fig. 1b). To overcome this 
issue, we used the endothelial cells as internal control, which 
allowed correction of the TL of astrocytoma cells for age 
and for inter-individual variability (i.e. CS-TL). The CS-TL 
was significantly longer in  IDH1R132H-mutated tumors as 
compared to  IDH1WT tumors (Fig. 1c) irrespective of tumor 
grade (Fig. 1d), while there were no significant differences 
among the different tumor types (p = 0.19, Supplementary 
Figure S1C).  IDH1R132H mutation was significantly asso-
ciated with improved patient survival (HR 0.28; 95% CI 
0.14–0.50; p < 0.001, Supplementary Figure S1C) with simi-
lar tendency (HR 0.47; 95% CI 0.21–1.08; p = 0.076) when 
adjusting for age and WHO grade. CS-TL did not signifi-
cantly correlate with prognosis (HR 0.98; p = 0.95) (Fig. 1e). 
However, when dichotomizing patients based on IDH1 status 
and CS-TL, patients with  IDH1R132-mutated tumors and long 
CS-TL had significantly poorer survival than patients with 
 IDH1R132-mutated tumors and short CS-TL (HR 1.80; 95% 
CI 1.03–3.16; p = 0.030, Fig. 1F). No significant prognostic 
value was found for patients with  IDHWT tumors (HR 0.98; 
95% CI 0.59–1.65; p = 0.95, Fig. 1f).
hTERT promoter mutations, IDH1 mutations, 
and telomere length
The incidence of  TERTpmut was 43% of which 84% harbored 
a C228T point mutation and 16% had a C250T point muta-
tion (Supplementary Figure S2A) (Table 1). The presence of 
 TERTpmut was associated with  IDH1WT (p = 0.007) (Fig. 2a).
TERTpmut tumors had slightly shorter CS-TL than 
 TERTpWT tumors (p = 0.05) (Fig.  2b). When analyzing 
CS-TL according to IDH1 and  TERTpmut status, we con-
firmed the increased CS-TL of  IDH1R132 tumors but did not 
found significant differences of CS-TL beween  IDH1WT/
TERTpWT and  IDH1WT/TERTpmut or  IDH1R132H/TERTpWT 
and  IDH1R132H/TERTpmut tumors (Fig. 2c).
TERTp status was significantly associated with reduced 
survival (HR 2.05; 95% CI 1.10–3.86; p = 0.022) in the entire 
cohort (Fig. 2d). However, in patients with an  IDH1R132H 
tumor, TERTp status did not significantly associate with 
survival (Fig. 2e), and multivariate analysis unveiled that 
TERTp status was not an independent prognostic factor 
when adjusting for age, WHO grade, and IDH1 status (HR 
1.06; 95% CI 0.50–2.24; p = 0.87).
ALT, ATRX mutations and telomere length
Using telomere FISH, we studied the presence of ALT 
 (ALTpos) on a single cell level in our cohort (Fig. 3a). 37% 
of the patients had  ALTpos tumors (Table 1) of which 100% 
also had an  IDH1R132H mutation (Fig. 3b). Further, loss of 
ATRX expression (Fig. 3c) and  TERTpWT (Fig. 3d) were 
associated with the presence of ALT. Both, presence of ALT 
and loss of ATRX expression were significantly associated 
with longer telomeres (p < 0.001, Fig. 3e, f) and improved 
survival (HR 0.42; 95% CI 0.22–0.81; p = 0.007 and HR 
0.46; 95% CI 0.4–0.85; p = 0.012, respectively; Fig. 3g, h). 
However, this association disappeared when adjusting for 
age, WHO grade and IDH1 status i a multi-variate analysis 
(ALT status: HR 0.62; 95% CI 0.23–1.72; p = 0.36; ATRX 
status: HR 1.12; 95% CI 0.43–2.93; p = 0.82).
In vitro overexpression of mutant  IDHR132H in a GBM 
cell line
To understand the role of  IDH1R132H mutations in regulating 
CS-TL in glioma, we used a doxycycline-inducible GBM 
cell line (LN319) expressing  IDH1WT and  IDH1R132H. The 
cell line was previously described and the presence of the 
 IDH1R132H mutation was confirmed by sequencing [39]. 
 IDHR132H expression induced by doxycycline significantly 
stimulated D2HG synthesis (p = 0.01; Fig. 4a), and com-
promised proliferation and clonogenicity (Supplementary 
Figure S3A-B). In this in vitro model, induced  IDH1R132H 
overexpression also resulted in a significant increase in TL 
after nine population doublings (Fig. 4b; Supplementary 
Figure S3C) and a significant downregulation of ATRX 
at transcriptional level (Fig. 4c). Telomere FISH detected 
a significant increase in  ALTpos cells in  IDH1R132H cells 
(Fig. 4d, left panels) and loss of ATRX protein expression 
7Journal of Neuro-Oncology (2020) 147:1–14 
1 3
(Fig. 4d) middle panels). Induced  IDHR132H overexpres-
sion neither altered the  TERTpmut status after short or 
long-term culture (Supplementary Figure S3D) nor signifi-
cantly increased TERT mRNA expression level (Fig. 4e). 
Fig. 2  TERT promotor, glioma cell-specific telomere length and 
IDH status. a Distribution of  IDH1WT and  IDH1R132H among the 
 TERTpmut and  TERTpWT patients (p = 0.001,  X2-test). b Glioma-
specific telomere length (CS-TL, in arbitrary units, a.u.) in  TERTpWT 
and  TERTpmut tumors. c CS-TL (in a.u.) of glioma patients accord-
ing to IDH1 and  TERTpmut status. d Kaplan–Meier survival curves of 
 TERTpWT and  TERTpmut patients. e Kaplan–Meier survival curves of 
 TERTpWT and  TERTpmut patients stratified after IDH1 status
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1 3
9Journal of Neuro-Oncology (2020) 147:1–14 
1 3
Immunofluorescence for TERT protein expression with 
DAPI counterstaining (Fig. 4d, right panels) illustrated the 
TERT-independent increase of TL in  IDHR132H cells.
Discussion
Maintenance mechanisms of telomeres are promising thera-
peutic targets and small molecule telomerase inhibitors are 
currently tested in clinical trials and filed for approval for the 
treatment of myeloproliferative syndromes [40, 41]. Exact 
understanding of telomere biology in glioma is therefore of 
high translational importance, given the completely diverse 
prognostic impact of TERTp mutations according to the 
IDH1 mutation status. Here we provide evidence suggest-
ing that glioma subgroups with and without IDH1 mutations 
use different TMM and describe a new pathway linking the 
 IDH1R132H mutations to ALT.
One major limitation of published studies on telomere 
biology in solid cancer was missing availability of tech-
niques that allow the determination of TL on a single cell 
level. In most studies performed so far [42–44], TL in tumor 
samples was actually derived from a mixture of vessels, 
immune cells and normal brain or tumor cells. This impaired 
significantly the validity and robustness of such studies. Fur-
thermore, these studies rarely controlled for inter-individual 
(mostly genetic) variability of TL or the presence of ALT. 
In our study, we developed a modified immuno-Q-FISH 
technique for the determination of the TL in glioma cells 
at a single cell level, thus allowing to overcome some of 
these limitations not only by measuring tumor cells individu-
ally but also by using endogenous endothelial cells as non-
malignant controls. Using this technique, we could show 
an increased CS-TL in  IDH1R132H mutated as compared to 
 IDH1WT tumors.
Concerning the role of ARTX mutations in gliomas [21, 
23, 26–28], we confirmed the association with survival[45] 
and with ALT[21] as well as the association among ALT, 
ATRX expression loss, and  IDH1R132H. However, the sam-
ples size of our cohort does not allow sound conclusions the 
prognostic relevance of the different TMM and the lacking 
association of ALT and TERTp mutations in the multivari-
ate analysis have to be interpreted with caution. In line with 
Heidenreich et al. [42], our data supports the evidence that 
 TERTpmut are associated with shorter TL in gliomas.
Here we showed that the  IDH1R132H mutation is directly 
associated with a lack of ATRX expression and conse-
quently, ALT as described previously [46]. In our sample, 
all tumors with ALT bear  IDH1R132H mutations and lost 
ATRX expression. Together with the inverse association 
of ALT with  TERTpmut, our data suggests that ALT is 
the major TMM in  IDH1R132H astrocytoma. Conversely, 
TERTp mutations appear to be the crucial TMM in  IDHWT 
astrocytoma.
Our data suggests a dichotomy of mechanisms in astro-
cytoma depending on the presence of IDH1 mutations 
(Fig. 5). In one tumor with TERTp mutations and ALT, the 
co-existance of two distinct TMM in  IDH1R132H cells of the 
same tumor (ALT and telomerase-dependent mechanisms) 
may exist, similar to the mosaic hypothesis previously sug-
gested for other tumor types, e.g. sarcomas [47]. The pro-
posed dichotomy indicates that treatment strategies targeting 
telomere maintenance, e.g. treatment with telomerase-inhib-
itors or ALT targeted treatment such e.g. PARP inhibitors 
or ATRX directed drugs [48, 49], must be personalized to 
the patient according to TMM. It is likely that the use of 
telomerase inhibitors can be ineffective or even detrimen-
tal in treating patients with  IDHR132H gliomas. Thus, the 
determination of ALT could be usefull as predictive marker 
to identify patients not responding to telomerase inhibitors.
We also showed that overexpression of  IDH1R132H in gli-
oma cells in vitro result in a phenotype that fully mimicked 
all phenomena observed in the patient samples. Overex-
pression of  IDH1R132H in the glioma cells resulted in D2HG 
production, decreased proliferation in vitro, loss of ATRX 
expression in vitro and ALT. Reduced ATRX expression 
due to  IDH1R132H overexpression suggests that  IDH1R132H 
alone is sufficient to diminish ATRX expression and thereby 
induce ALT. However, the importance and functional rel-
evance of this mechanism needs to be further confirmed 
in vivo. Further, it remains to be clarified, why  IDHR132H 
mutated glioma cells favor ATRX mutations, although there 
is a second, alternative pathway to suppress ATRX.
An obvious mechanism linking  IDH1R132H phenotype to 
the loss of ATRX in human glioma may be the existence of 
a typical hypermethylation/CpG island methylation of the 
ATRX gene. Our data partially supports the results found by 
Ohba et al. [50], who showed that IDH1 mutations do not 
select for or induce ATRX mutations or  TERTpmut. How-
ever, we found no significant reactivation of TERT.
In conclusion, we found that ALT is the major TMM in 
 IDH1R132H astrocytomas and that  IDH1R132H mutations can 
directly suppress ATRX expression resulting in ALT.
Fig. 3  ATRX, alternative lengthening and survival. a Representa-
tive images showing Q-FISH stained gliomas with  (ALTpos) and 
without ALT  (ALTneg, magnification: 756x). b Number of  IDH1WT 
and  IDH1R132 patients stratified according to ALT status. c Num-
ber of  ATRXWT and  ATRXmut patients stratified according to ALT 
status. d Number of  TERTpWT and  TERTpmut patients stratified 
according to ALT status. e Glioma-specific telomere length (CS-TL 
in arbitrary units, a.u.) in  ALTneg and  ALTpos tumors. f Glioma-spe-
cific telomere length (CS-TL in arbitrary units, a.u.) in tumors with 
retained  (ATRXret) ATRX and in tumors with ATRX loss  (ALTloss). g 
Kaplan–Meier survival curves (in months) of glioma patients accord-
ing to ALT status. h Kaplan–Meier survival curves (in months) of 
glioma patients according to ATRX mutational status
◂
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Fig. 4  Telomerelength after induction of  IDH1R132H expression. a 
Production of the metabolite (inM) in the glioma cell line LN319 
after the doxycycline-induced overexpression of  IDH1R132H and 
control conditions. D2HG was measured in the medium supernatant 
after three population doublings in culture. b Telomere length in the 
doxycycline induced  IDH1WT and  IDH1R132H cell lines, after nine 
population doublings in culture  (IDH1WT = 33.76 ± 1.54 a.u, n = 48 
vs.  IDH1R132H = 47.3 ± 1.93 a.u, n = 29). c Fold change of ATRX 
mRNA expression after doxycycline treatment and nine popula-
tion doublings as compared to untreated controls. d Representative 
images of Q-FISH stained doxycycline induced  IDH1WT (upper row) 
and  IDH1R132H cell lines (lower row). All images correspond to cell 
culture after 14 population doublings. The presence of ALT (left 
panel: telomere FISH (red), DAPI counterstaining), ATRX protein 
expression (middle panel: ATRX immunofluorescence (green), DAPI 
counterstaining), and TERT expression (right panel: TERT immuno-
fluorescence (green), DAPI counterstaining) is given (magnification 
756x). e TERT expression levels (fold change) at the mRNA level 
of doxycycline-induced  IDH1WT and  IDH1R132H cell lines after nine 
population doublings in culture
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